Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Bright Minds Biosciences Inc.
Market Cap
$487.30M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$491.55M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$491.93M
EBITDA Margin
-9.71%
TTM Avg
-10.19%
3Y Avg
-20.82%
5Y Avg
-63.11%
Market Cap
$481.33M
EBITDA Margin
-41.77%
TTM Avg
-67.13%
3Y Avg
-207.81%
5Y Avg
-270.93%
Market Cap
$478.54M
EBITDA Margin
-31.76%
TTM Avg
-31.76%
3Y Avg
-31.76%
5Y Avg
-31.76%
Market Cap
$471.57M
EBITDA Margin
-3.52%
TTM Avg
-5.19%
3Y Avg
-11.78%
5Y Avg
-23.46%
Market Cap
$517.73M
EBITDA Margin
-1179818.18%
TTM Avg
-754929.09%
3Y Avg
-428982.67%
5Y Avg
-428982.67%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bright Minds Biosciences Inc. (DRUG) | $487.30M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | 0.24% | -1.36% | -6.49% | -5.53% |
| Evolus, Inc. (EOLS)vs › | $491.93M | -9.71% | -10.19% | -20.82% | -63.11% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | -41.77% | -67.13% | -207.81% | -270.93% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -31.76% | -31.76% | -31.76% | -31.76% |
| Cerus Corporation (CERS)vs › | $471.57M | -3.52% | -5.19% | -11.78% | -23.46% |
| NRC Health (NRC)vs › | $468.31M | 21.99% | 25.40% | 28.98% | 31.97% |
| Kamada Ltd. (KMDA)vs › | $461.55M | 22.80% | 21.92% | 17.96% | 15.83% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -1179818.18% | -754929.09% | -428982.67% | -428982.67% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -1406.75% | -1406.75% | -151851.64% | -92301.39% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
